ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Radical shift required in use of heart medicine worldwide

Many people in the world who need essential heart medicine do not get it, even in rich countries, says new research published today in the medical journal The Lancet.

22 Oct 2015

Common hypertension drugs worsen cardiovascular outcomes in hypertensive African Americans

Drugs commonly used to treat high blood pressure, and prevent heart attacks and strokes, are associated with significantly worse cardiovascular outcomes in hypertensive African Americans compared to whites, according to a new comparative effectiveness research study led by researchers in the Department of Population Health at NYU Langone Medical Center.

15 Sep 2015

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern Medical Center has joined an international clinical trial studying whether a drug traditionally used to treat gout can help prevent kidney damage in patients with Type 1 diabetes.

15 Sep 2015

Researchers elucidate mechanism that induces skeletal muscle atrophy in patients with congestive heart failure

It is a paradox: Patients with advanced congestive heart failure lose skeletal muscle mass, but their heart muscles become enlarged to provide the body with an adequate supply of blood and thus with oxygen. It has long been known that the protein angiotensin II plays a villainous role in this process, but the exact mechanism has remained unclear.

12 Aug 2015

Commonly prescribed drug also lowers blood pressure when combined with diuretic

With the growth of electronic medical records, research utilizing data from a large number of patients, known as big data studies, can provide important information which may be unattainable via clinical trials which tend to be costly, time-consuming and involve fewer patients.

30 Jul 2015

No significant research undertaken to prevent or treat PPCM in healthy pregnant women, study reveals

Peripartum cardiomyopathy (PPCM) is a rare disorder characterized by weakened pumping of the heart, or "left ventricular dysfunction," which results in otherwise healthy pregnant women experiencing heart failure shortly before or up to five months after they deliver healthy babies. Despite the seriousness of this condition, a new study published in the Canadian Journal of Cardiology revealed that no significant research has been undertaken to explore how to prevent or treat this disorder.

16 Jul 2015

FDA approves new heart failure drug

A new drug called Entresto has been approved by the U.S Food and Drug Administration (FDA) for the treatment of heart failure.

9 Jul 2015

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Novartis announced today that the US Food and Drug Administration has approved Entresto™ tablets, previously known as LCZ696, to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction.

8 Jul 2015

Statins reduce risk of death by 67% in CABG surgery

Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications.

1 Jun 2015

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights.

19 Feb 2015

Novartis’ heart failure medicine LCZ696 granted FDA priority review

LCZ696, a twice-a-day medicine being investigated for heart failure, acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.

30 Dec 2014

Australian Prescriber publishes top 10 subsidised drugs in Australia

The annual publication of the top 10 subsidised drugs appears in the December edition of Australian Prescriber. Statins (cholesterol-lowering medicines) top the lists again.

1 Dec 2014

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA.

18 Nov 2014

Study suggests that beta blockers may benefit patients suffering from HFPEF

A novel registry study from Karolinska Institutet in Sweden suggests that beta blockers may benefit also patients suffering from a relatively unknown form of heart failure called HFPEF, which today lacks well-established treatment.

17 Nov 2014

Women prescribed different medication than men to bring down blood pressure

Women who are treated for high blood pressure are not given the same medication as men, nor do they hit the treatment targets as often, reveals a thesis from the University of Gothenburg.

14 Oct 2014

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas.

15 Sep 2014

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure).

9 Sep 2014

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).

8 Sep 2014